Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
73
PBE Quote, Financials, Valuation and Earnings
Last price:
$84.17
Seasonality move
:
0.29%
Day range:
$83.92 - $84.17
52-week range:
$54.52 - $84.17
Dividend yield:
0.97%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
32.9K
Avg. volume:
6.7K
1-year change:
24.75%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$84.16 | -- | -- | -- | $0.42 | 0.97% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$215.07 | -- | -- | -- | $1.17 | 0% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$108.08 | -- | -- | -- | $0.25 | 0.95% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$89.57 | -- | -- | -- | $0.02 | 0.08% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.29 | -- | -- | -- | $0.12 | 0.27% | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$57.56 | -- | -- | -- | $0.11 | 0.81% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.657 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.316 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 1.031 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.588 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About PBE or FBT?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe Invesco Biotechnology & Genome ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is PBE or FBT More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.562%.
-
Which is a Better Dividend Stock PBE or FBT?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 0.97%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0% to investors and pays a quarterly dividend of $1.17 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or FBT?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.387%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 0.97%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.25 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.522%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 0.97%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns PBE or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About PBE or XHS?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is PBE or XHS More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock PBE or XHS?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 0.97%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.27% to investors and pays a quarterly dividend of $0.12 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHS?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
State Street SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.268%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 0.97%. State Street SPDR S&P Pharmaceuticals ETF offers a yield of 0.81% to investors and pays a quarterly dividend of $0.11 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
